Review Article
Volume 9 Issue 11 - 2020
Current Knowledge on Neonatal Alloimmune Thrombocytopenia’s Pathogenesis, Clinical Presentation, Diagnostic and Management
Gilberto Soler Noda1*, Yisenia Romero Díaz2, Mariela Forrellat Barrios3 and Antonio Bencomo Hernández4
1Auxiliar Professor, Auxiliar Investigator, Laboratory of Immunohematology, Institute of Hematology and Immunology, College of Health Technology, Medical University of Habana, La Habana, Cuba
2Specialist in Biochemistry and Molecular Biology, Aggregate Investigator, Laboratory of Immunohematology, Institute of Hematology and Immunology, La Habana, Cuba
3Auxiliar Professor, Auxiliar Investigator, Institute of Hematology and Immunology, La Habana, Cuba
4Senior Investigator, Institute of Hematology and Immunology, La Habana, Cuba
*Corresponding Author: Gilberto Soler Noda, Auxiliar Professor, Auxiliar Investigator, Laboratory of Immunohematology, Institute of Hematology and Immunology, College of Health Technology, Medical University of Habana, La Habana, Cuba.
Received: September 16, 2020; Published: October 07, 2020


Neonatal alloimmune thrombocytopenia is a disease caused by maternal antibodies against fetal platelet antigens inherited from the father. It can cause intracranial bleeding and lead to death or disability in the fetus/neonate. Although it is the most serious cause of thrombocytopenia in the neonate and the most common in term newborns, it has generally been poorly investigated. The pathophysiology of the disease is very similar to that of perinatal hemolytic disease; maternal IgG antibodies are transported through the placenta to the fetal circulation, opsonizing fetal platelets which are removed by phagocytosis. The antigens most implicated are HPA- 1a and HPA-4a. The clinical impact of this entity and the treatment opportunities enhance the need to implement screening programs for the detection of fetuses at risk of suffering from it, where the diagnosis is generally made after the birth of the child affected by thrombocytopenia, intracranial hemorrhage or death in utero of unexplained cause.

Keywords: Neonatal Alloimmune Thrombocytopenia; NAIT; Human Platelet Antigens; HPA; Pregnancy; Platelet Alloimmunization



  1. Brojer E., et al. “Fetal/Neonatal Alloimmune Thrombocytopenia: Pathogenesis, Diagnostics and Preventionˮ. Archivum Immunologiae et Therapiae Experimentalis 64 (2016): 279-290.
  2. Metcalfe P., et al. “Nomenclature of Human Platelet Antigensˮ. Vox Sanguinis 85 (2003): 240-245.
  3. Peterson J., et al. “New platelet glycoprotein polymorphisms causing maternal immunization and neonatal alloimmune thrombocytopeniaˮ. Transfusion 52 (2012): 1117-1124.
  4. Curtis BR and McFarland JG. “Human platelet antigens- 2013ˮ. Vox Sanguinis 106 (2014): 93-102.
  5. Zdravic D., et al. “Fetal and neonatal alloimmune thrombocytopeniaˮ. Seminars in Fetal and Neonatal Medicine 21 (2016): 19-27.
  6. Curtis BR. “Recent progress in understanding the pathogenesis of fetal and neonatal alloimmune thrombocytopeniaˮ. British Journal of Haematology 171 (2015): 671-682.
  7. Kamphuis MM., et al. “Incidence and consequences of neonatal alloimmune thrombocytopenia: a systematic reviewˮ. Pediatrics 133 (2014): 715-721.
  8. Vadasz Brian PC., et al. “Platelets and platelet alloantigens: lessons from human patients and animal models of fetal and neonatal alloimmune thrombocytopeniaˮ. Genes and Diseases 2 (2015): 173-185.
  9. Dubruc E., et al. “Placental histological lesions in fetal and neonatal alloimmune thrombocytopenia: A retrospective cohort study of 21 casesˮ. Placenta 48 (2016): 104-109.
  10. Strong NK and Eddleman KA. “Diagnosis and Management of Neonatal Alloimmune Thrombocytopenia in Pregnancyˮ. Clinics in Laboratory Medicine 33 (2013): 311-325.
  11. Zucker MB., et al. “Thrombocytopenia with circulating platelet agglutinin, platelet agglutinin, platelet lysine and clat retraction inhibitorˮ. Blood 14 (1959): 148-161.
  12. Shulman NR., et al. “Immunoreactions involving platelet.VI: Reactions of maternal isoantibodies responsible for neonatal purpura. Differentiation of a second platelet antigen systemˮ. Journal of Clinical Investigation 41 (1962): 1059-1069.
  13. Aster RH and Newman PJ. “HPA-1a/b (PLA1/A2, Zwa/b): The Odyssey of an alloantigen systemˮ. Immunohematology 23 (2007): 1-8.
  14. Wu GG. “Detection of clinically relevant platelet antibodies in the Asian populationˮ. The ISBT Science Series 9 (2014): 112-117.
  15. Norton A., et al. “Review. Platelet alloantigens and antibodies and clinical significanceˮ. Immunohematology 20 (2004): 89-99.
  16. Winkelhorst D., et al. “Severe bleeding complications other than intracranial hemorrhage in neonatal alloimmune thrombocytopenia: a case series and review of the literatureˮ. Transfusion 56 (2016): 1230-1235.
  17. Delbos F., et al. “Fetal and neonatal alloimmune thrombocytopenia: predictive factors of intracranial hemorrhageˮ. Transfusion 56 (2016): 59-66.
  18. Santoso S., et al. “Antiendothelial alphavbeta3 antibodies are a major cause of intracranial bleeding in fetal/neonatal alloimmune thrombocytopeniaˮ. Arteriosclerosis, Thrombosis, and Vascular Biology 36 (2016): 1517-1524.
  19. Yougbaré I., et al. “Maternal anti-platelet β3 integrins impair angiogenesis and cause intracranial hemorrhageˮ. Journal of Clinical Investigation 125 (2015): 1545-1556.
  20. Murphy MF., et al. “Severe fetomaternal alloimmune thrombocytopenia presenting with fetal hydrocephalusˮ. Prenatal Diagnosis 16 (1996): 1152-1155.
  21. Stanworth SJ., et al. “Fetomaternal alloimmune thrombocytopenia presenting antenatal as hydrops fetalisˮ. Prenatal Diagnosis 21 (2001): 423-424.
  22. Muñiz E and Ginovart G. “Trombocitopenia aloinmune en el feto y en el recién nacidoˮ. Pediatric Annals 58 (2003): 562-567.
  23. Campbell-Lee SA., et al. “Neonatal alloimmune thrombocytopenia due to anti-HPA-5b (Bra)ˮ. Immunohematology 19 (2003): 127-131.
  24. Kaplan C. “Neonatal alloimmune thrombocytopenia: a 50 year storyˮ. Immunohematology 23 (2007): 9-13.
  25. Tiller H., et al. “Current perspectives on fetal and neonatal alloimmune thrombocytopenia – increasing clinical concerns and new treatment opportunitiesˮ. International Journal of Women’s Health 9 (2017): 223-234.
  26. Soler Noda G., et al. “Trombocitopenias neonatales en La Habana: incidencia y características de la enfermedadˮ. Revista Cubana de Hematología, Inmunología y Hemoterapia 33 (2017).
  27. Bessos H., et al. “Is there a relationship between anti-HPA-1a concentration and severity of neonatal alloimmune thrombocytopenia?ˮ Immunohematology 21 (2005): 102-108.
  28. Kaplan C., et al. “Management of alloimmune thrombocytopenia: antenatal diagnosis and in utero transfusion of maternal plateletsˮ. Blood 72 (1998): 340-343.
  29. Winkelhorst D., et al. “Antenatal management in fetal and neonatal alloimmune thrombocytopenia: a systematic reviewˮ. Blood 129 (2017): 1538-1547.
  30. Williamson LM., et al. “The natural history of fetomaternal alloimmunization to the platelet specific antigen HPA-1a(PLA1, Zwa) as determined by antenatal screeningˮ. Blood 92 (1998): 2280-2287.
  31. Sainio S., et al. “Usefulness of maternal anti-HPA-1a antibody quantitation in predicting severity of foetomaternal alloimmune thrombocytopeniaˮ. Transfusion Medicine 23 (2013): 114-120.
  32. Allen D., et al. “Interlaboratory variation in the detection of HPA-specific alloantibodies and in molecular HPA typingˮ. Vox Sanguinis 93 (2007): 316-324.
  33. Metcalfe P., et al. “An International Reference Reagent (minimum sensitivity) for the detection of anti-human platelet antigen 1aˮ. Vox Sanguinis 96 (2009): 146-152.
  34. Wienzek-Lischka S., et al. “HLA-DRB3*01:01 is a predictor of immunization against human platelet antigen-1a but not of the severity of fetal and neonatal alloimmune thrombocytopeniaˮ. Transfusion 57 (2017): 533-540.
  35. Sainio S., et al. “Maternal HLA genotyping is not useful for predicting severity of fetal and neonatal alloimmune thrombocytopeniaˮ. British Journal of Haematology 176 (2017): 111-117.
  36. Semana G., et al. “Genetic susceptibility and anti-human platelet antigen 5b alloimmunization. Role of HLA class II and TAP genesˮ. Human Immunology 46 (1996): 114-119.
  37. Westman P., et al. “Maternal DRB1*1501, DQA1*0102, DQB1*0602 haplotipe in fetomaternal alloimmunization against human platelet alloantigen HPA-6b (GPIIIa-Gln489) ˮ. Tissue Antigens 50 (1997): 113-118.
  38. Peterson JA., et al. “Neonatal alloimmune thrombocytopenia: pathogenesis, diagnosis and managementˮ. British Journal of Haematology 161 (2013): 3-14.
  39. Brown M and Wittwer C. “Flow cytometry: principles and clinical applications in hematologyˮ. Clinical Chemistry 46 (2000): 1221-1229.
  40. Avent ND. “Prenatal testing for hemolytic disease of the newborn and fetal neonatal alloimmune thrombocytopenia - current statusˮ. Expert Review of Hematology 7 (2014): 741-745.
  41. Von Dem Borne AEGKr., et al. “A Simple Immunofluorescence Test for the Detection of Platelet Antibodiesˮ. British Journal of Haematology 39 (1978): 195-207.
  42. Jain N., et al. “Detection and identification of platelet-associated alloantibodies by a solid-phase modified antigen capture enzyme-linked immunosorbent assay method and its correlation to platelet refractoriness in multiplatelet concentrate-transfused patientsˮ. Immunohematology 30 (2014): 123-125.
  43. Sarkar RS., et al. “Detection and Identification of Platelet-Associated Alloantibodies by a Solid-Phase Modified Antigen Capture Elisa (MACE) Technique and Its Correlation to Platelet Refractoriness in Multi platelet Concentrate Transfused Patientsˮ. Indian Journal of Hematology and Blood Transfusion 31 (2015): 77-84.
  44. Maslanka K., et al. “The relevance of HPA-15 antigen expression for anti-HPA-15 antibody detectionˮ. International Journal of Laboratory Hematology 34 (2012): 65-69.
  45. Porcelijn L., et al. “A new bead-based human platelet antigen antibodies detection assay versus the monoclonal antibody immobilization of platelet antigens assayˮ. Transfusion 54 (2014): 1486-1492.
  46. Arinsburg SA., et al. “Determination of human platelet antigen typing by molecular methods: importance in diagnosis and early treatment of neonatal alloimmune thrombocytopeniaˮ. American Journal of Hematology 87 (2012): 525-528.
  47. Hayashi T and Hirayama F. “Advances in alloimmune thrombocytopenia: perspectives on current concepts of human platelet antigens, antibody detection strategies, and genotypingˮ. Blood Transfus 13 (2015): 380-390.
  48. Wienzek-Lischka S., et al. “Noninvasive fetal genotyping of human platelet antigen-1a using targeted massively parallel sequencingˮ. Transfusion 55 (2015): 1538-1544.
  49. Curtis BR and McFarland JG. “Detection and identification of platelet antibodies and antigens in the clinical laboratoryˮ. Immunohematology 25 (2009): 125-135.
  50. Ghevaert C., et al. “Alloantibodies against low-frequency human platelet antigens do not account for a significant proportion of cases of fetomaternal alloimmune thrombocytopenia: evidence from 1054 casesˮ. Transfusion 49 (2009): 2084-2089.
  51. Ronzoni S., et al. “Antenatal management of fetal neonatal alloimmune thrombocytopenia (FNAIT) and neonatal outcome according to the category of riskˮ. Ultrasound in Obstetrics and Gynecology 48 (2016): 357.
  52. Masson E., et al. “Incidence and risk factors of anti-HLA immunization after pregnancyˮ. Human Immunology 74 (2013): 946-951.
  53. Zhu J., et al. “Structure of a complete integrin ectodomain in a physiologic resting state and activation and deactivation by applied forcesˮ. Molecular Cell 32 (2008): 849-861.
  54. Jallu V., et al. “The alphaIIb p. Leu841Met (Cab3(a+)) polymorphism results in a new human platelet alloantigen involved in neonatal alloimmune thrombocytopenia”. Transfusion (2012).
  55. Peterson JA., et al. “Prevalence and clinical significance of low-avidity HPA-1a antibodies in women exposed to HPA-1a during pregnancyˮ. Transfusion (2012).
  56. Tsuno NH., et al. “The importance of platelet antigens and antibodies in immune-mediated thrombocytopeniaˮ. Vox Sanguinis 9 (2014): 104-111.
  57. Van Der Lugt NM., et al. “Neonatal outcome in alloimmune thrombocytopenia after maternal treatment with intravenous immunoglobulinˮ. Blood Transfus 13 (2015): 66-71.
  58. Tiller H., et al. “True risk of fetal/neonatal alloimmune thrombocytopenia in subsequent pregnancies: a prospective observational follow-up studyˮ. BJOG 123 (2016): 738-744.
  59. Winkelhorst D., et al. “Fetal and neonatal alloimmune thrombocytopenia: evidence based antenatal and postnatal management strategiesˮ. Expert Review of Hematology 10 (2017): 729-737.
  60. Rossi KQ., et al. “Effects of antepartum therapy for fetal alloimmune thrombocytopenia on maternal lifestyleˮ. Journal of Maternal-Fetal and Neonatal Medicine 29 (2016): 1783-1788.
  61. Paridaans NP., et al. “Low-dose versus standard-dose intravenous immunoglobulin to prevent fetal intracranial hemorrhage in fetal and neonatal alloimmune thrombocytopenia: a randomized trialˮ. Fetal Diagnosis and Therapy 38 (2015): 147-153.
Citation: Gilberto Soler Noda., et al. “Current Knowledge on Neonatal Alloimmune Thrombocytopenia’s Pathogenesis, Clinical Presentation, Diagnostic and Management”. EC Paediatrics 9.11 (2020): 39-49.

PubMed Indexed Article

EC Pharmacology and Toxicology
LC-UV-MS and MS/MS Characterize Glutathione Reactivity with Different Isomers (2,2' and 2,4' vs. 4,4') of Methylene Diphenyl-Diisocyanate.

PMID: 31143884 [PubMed]

PMCID: PMC6536005

EC Pharmacology and Toxicology
Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics.

PMID: 31565701 [PubMed]

PMCID: PMC6764777

EC Neurology
Differences in Rate of Cognitive Decline and Caregiver Burden between Alzheimer's Disease and Vascular Dementia: a Retrospective Study.

PMID: 27747317 [PubMed]

PMCID: PMC5065347

EC Pharmacology and Toxicology
Will Blockchain Technology Transform Healthcare and Biomedical Sciences?

PMID: 31460519 [PubMed]

PMCID: PMC6711478

EC Pharmacology and Toxicology
Is it a Prime Time for AI-powered Virtual Drug Screening?

PMID: 30215059 [PubMed]

PMCID: PMC6133253

EC Psychology and Psychiatry
Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse.

PMID: 30417173 [PubMed]

PMCID: PMC6226033

EC Anaesthesia
Arrest Under Anesthesia - What was the Culprit? A Case Report.

PMID: 30264037 [PubMed]

PMCID: PMC6155992

EC Orthopaedics
Distraction Implantation. A New Technique in Total Joint Arthroplasty and Direct Skeletal Attachment.

PMID: 30198026 [PubMed]

PMCID: PMC6124505

EC Pulmonology and Respiratory Medicine
Prevalence and factors associated with self-reported chronic obstructive pulmonary disease among adults aged 40-79: the National Health and Nutrition Examination Survey (NHANES) 2007-2012.

PMID: 30294723 [PubMed]

PMCID: PMC6169793

EC Dental Science
Important Dental Fiber-Reinforced Composite Molding Compound Breakthroughs

PMID: 29285526 [PubMed]

PMCID: PMC5743211

EC Microbiology
Prevalence of Intestinal Parasites Among HIV Infected and HIV Uninfected Patients Treated at the 1o De Maio Health Centre in Maputo, Mozambique

PMID: 29911204 [PubMed]

PMCID: PMC5999047

EC Microbiology
Macrophages and the Viral Dissemination Super Highway

PMID: 26949751 [PubMed]

PMCID: PMC4774560

EC Microbiology
The Microbiome, Antibiotics, and Health of the Pediatric Population.

PMID: 27390782 [PubMed]

PMCID: PMC4933318

EC Microbiology
Reactive Oxygen Species in HIV Infection

PMID: 28580453 [PubMed]

PMCID: PMC5450819

EC Microbiology
A Review of the CD4 T Cell Contribution to Lung Infection, Inflammation and Repair with a Focus on Wheeze and Asthma in the Pediatric Population

PMID: 26280024 [PubMed]

PMCID: PMC4533840

EC Neurology
Identifying Key Symptoms Differentiating Myalgic Encephalomyelitis and Chronic Fatigue Syndrome from Multiple Sclerosis

PMID: 28066845 [PubMed]

PMCID: PMC5214344

EC Pharmacology and Toxicology
Paradigm Shift is the Normal State of Pharmacology

PMID: 28936490 [PubMed]

PMCID: PMC5604476

EC Neurology
Examining those Meeting IOM Criteria Versus IOM Plus Fibromyalgia

PMID: 28713879 [PubMed]

PMCID: PMC5510658

EC Neurology
Unilateral Frontosphenoid Craniosynostosis: Case Report and a Review of the Literature

PMID: 28133641 [PubMed]

PMCID: PMC5267489

EC Ophthalmology
OCT-Angiography for Non-Invasive Monitoring of Neuronal and Vascular Structure in Mouse Retina: Implication for Characterization of Retinal Neurovascular Coupling

PMID: 29333536 [PubMed]

PMCID: PMC5766278

EC Neurology
Longer Duration of Downslope Treadmill Walking Induces Depression of H-Reflexes Measured during Standing and Walking.

PMID: 31032493 [PubMed]

PMCID: PMC6483108

EC Microbiology
Onchocerciasis in Mozambique: An Unknown Condition for Health Professionals.

PMID: 30957099 [PubMed]

PMCID: PMC6448571

EC Nutrition
Food Insecurity among Households with and without Podoconiosis in East and West Gojjam, Ethiopia.

PMID: 30101228 [PubMed]

PMCID: PMC6086333

EC Ophthalmology
REVIEW. +2 to +3 D. Reading Glasses to Prevent Myopia.

PMID: 31080964 [PubMed]

PMCID: PMC6508883

EC Gynaecology
Biomechanical Mapping of the Female Pelvic Floor: Uterine Prolapse Versus Normal Conditions.

PMID: 31093608 [PubMed]

PMCID: PMC6513001

EC Dental Science
Fiber-Reinforced Composites: A Breakthrough in Practical Clinical Applications with Advanced Wear Resistance for Dental Materials.

PMID: 31552397 [PubMed]

PMCID: PMC6758937

EC Microbiology
Neurocysticercosis in Child Bearing Women: An Overlooked Condition in Mozambique and a Potentially Missed Diagnosis in Women Presenting with Eclampsia.

PMID: 31681909 [PubMed]

PMCID: PMC6824723

EC Microbiology
Molecular Detection of Leptospira spp. in Rodents Trapped in the Mozambique Island City, Nampula Province, Mozambique.

PMID: 31681910 [PubMed]

PMCID: PMC6824726

EC Neurology
Endoplasmic Reticulum-Mitochondrial Cross-Talk in Neurodegenerative and Eye Diseases.

PMID: 31528859 [PubMed]

PMCID: PMC6746603

EC Psychology and Psychiatry
Can Chronic Consumption of Caffeine by Increasing D2/D3 Receptors Offer Benefit to Carriers of the DRD2 A1 Allele in Cocaine Abuse?

PMID: 31276119 [PubMed]

PMCID: PMC6604646

EC Anaesthesia
Real Time Locating Systems and sustainability of Perioperative Efficiency of Anesthesiologists.

PMID: 31406965 [PubMed]

PMCID: PMC6690616

EC Pharmacology and Toxicology
A Pilot STEM Curriculum Designed to Teach High School Students Concepts in Biochemical Engineering and Pharmacology.

PMID: 31517314 [PubMed]

PMCID: PMC6741290

EC Pharmacology and Toxicology
Toxic Mechanisms Underlying Motor Activity Changes Induced by a Mixture of Lead, Arsenic and Manganese.

PMID: 31633124 [PubMed]

PMCID: PMC6800226

EC Neurology
Research Volunteers' Attitudes Toward Chronic Fatigue Syndrome and Myalgic Encephalomyelitis.

PMID: 29662969 [PubMed]

PMCID: PMC5898812

EC Pharmacology and Toxicology
Hyperbaric Oxygen Therapy for Alzheimer's Disease.

PMID: 30215058 [PubMed]

PMCID: PMC6133268

News and Events

January Issue Release

We always feel pleasure to share our updates with you all. Here, notifying you that we have successfully released the January issue of respective journals and can be viewed in the current issue pages.

Submission Deadline for January Issue

Ecronicon delightfully welcomes all the authors around the globe for effective collaboration with an article submission for the January issue of respective journals. Submissions are accepted on/before January 30, 2021.

Certificate of Publication

Ecronicon honors with a "Publication Certificate" to the corresponding author by including the names of co-authors as a token of appreciation for publishing the work with our respective journals.

Best Article of the Issue

Editors of respective journals will always be very much interested in electing one Best Article after each issue release. The authors of the selected article will be honored with a "Best Article of the Issue" certificate.

Certifying for Review

Ecronicon certifies the Editors for their first review done towards the assigned article of the respective journals.

Latest Articles

The latest articles will be updated immediately on the articles in press page of the respective journals.

Immediate Assistance

The prime motto of this team is to clarify all the queries without any delay or hesitation to avoid the inconvenience. For immediate assistance on your queries please don't hesitate to drop an email to